EBITDA Summary of Virbac SA

Virbac SA's latest annual EBITDA in 2023 was 230.65 Million EUR , down -6.08% from previous year.
Virbac SA's latest quarterly EBITDA in 2024 Q2 was 84.35 Million EUR , down 0.0% from previous quarter.
Virbac SA reported an annual EBITDA of 229.2 Million EUR in 2022, up 7.72% from previous year.
Virbac SA reported an annual EBITDA of 208.43 Million EUR in 2021, up 19.59% from previous year.
Virbac SA reported a quarterly EBITDA of 84.35 Million EUR for 2024 Q2, down 0.0% from previous quarter.
Virbac SA reported a quarterly EBITDA of N/A for 2023 FY, down -6.08% from previous quarter.

Annual EBITDA Chart of Virbac SA (2023 - 2002)

Historical Annual EBITDA of Virbac SA (2023 - 2002)

Year	EBITDA	EBITDA Growth
2023	230.65 Million EUR	-6.08%
2022	229.2 Million EUR	7.72%
2021	208.43 Million EUR	19.59%
2020	241.73 Million EUR	21.25%
2019	155.1 Million EUR	33.76%
2018	117.76 Million EUR	3.98%
2017	107.35 Million EUR	-10.86%
2016	109.48 Million EUR	49.14%
2015	77.68 Million EUR	-43.32%
2014	140.72 Million EUR	13.3%
2013	131.27 Million EUR	2.75%
2012	122.65 Million EUR	15.14%
2011	106.53 Million EUR	-0.41%
2010	106.97 Million EUR	43.61%
2009	74.49 Million EUR	8.28%
2008	68.51 Million EUR	7.64%
2007	63.91 Million EUR	11.57%
2006	54.53 Million EUR	4.41%
2005	50.01 Million EUR	38.51%
2004	41.23 Million EUR	21.59%
2003	32.57 Million EUR	-20.18%
2002	40.81 Million EUR	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	84.35 Million EUR	76.06%
2024 Q2	84.35 Million EUR	0.0%
2023 FY	- EUR	-6.08%
2023 Q2	124.04 Million EUR	96.48%
2023 Q3	47.91 Million EUR	-61.38%
2023 Q4	47.91 Million EUR	0.0%
2023 Q1	63.13 Million EUR	-27.39%
2022 Q1	66.38 Million EUR	-20.35%
2022 Q2	132.19 Million EUR	99.12%
2022 Q3	42.77 Million EUR	-67.64%
2022 Q4	86.95 Million EUR	103.27%
2022 FY	- EUR	7.72%
2021 Q4	83.34 Million EUR	99.81%
2021 FY	- EUR	19.59%
2021 Q2	120.09 Million EUR	101.74%
2021 Q1	59.52 Million EUR	-3.51%
2021 Q3	41.71 Million EUR	-65.27%
2020 FY	- EUR	21.25%
2020 Q2	99.65 Million EUR	99.19%
2020 Q1	50.03 Million EUR	-29.71%
2020 Q4	61.69 Million EUR	108.04%
2020 Q3	29.65 Million EUR	-70.24%
2019 Q2	39.64 Million EUR	0.0%
2019 Q4	71.18 Million EUR	103.92%
2019 FY	- EUR	33.76%
2019 Q3	34.9 Million EUR	-11.94%
2019 Q1	39.64 Million EUR	38.7%
2018 Q3	28.58 Million EUR	-5.68%
2018 FY	- EUR	3.98%
2018 Q2	30.3 Million EUR	0.0%
2018 Q1	30.3 Million EUR	17.87%
2018 Q4	28.58 Million EUR	0.0%
2017 Q3	25.7 Million EUR	-8.09%
2017 Q2	27.97 Million EUR	0.0%
2017 Q4	25.7 Million EUR	0.0%
2017 FY	- EUR	-10.86%
2017 Q1	27.97 Million EUR	-2.62%
2016 Q4	28.72 Million EUR	0.0%
2016 Q1	26.01 Million EUR	25.98%
2016 FY	- EUR	49.14%
2016 Q3	28.72 Million EUR	10.39%
2016 Q2	26.01 Million EUR	0.0%
2015 Q2	21.69 Million EUR	0.0%
2015 FY	- EUR	-43.32%
2015 Q4	20.65 Million EUR	0.0%
2015 Q3	20.65 Million EUR	-4.79%
2015 Q1	21.69 Million EUR	-41.6%
2014 Q1	32.37 Million EUR	3.07%
2014 FY	- EUR	13.3%
2014 Q3	37.14 Million EUR	14.74%
2014 Q4	37.14 Million EUR	0.0%
2014 Q2	32.37 Million EUR	0.0%
2013 Q1	35.16 Million EUR	0.0%
2013 FY	- EUR	2.75%
2013 Q3	31.4 Million EUR	-10.68%
2013 Q2	35.16 Million EUR	0.0%
2013 Q4	31.4 Million EUR	0.0%
2012 FY	- EUR	15.14%
2011 FY	- EUR	-0.41%
2010 FY	- EUR	43.61%
2009 FY	- EUR	8.28%
2008 FY	- EUR	7.64%
2007 FY	- EUR	11.57%
2006 FY	- EUR	4.41%
2005 FY	- EUR	38.51%
2004 FY	- EUR	21.59%
2003 FY	- EUR	-20.18%
2002 FY	- EUR	0.0%

Peer EBITDA Comparison of Virbac SA

Name	EBITDA	EBITDA Difference
AstraZeneca PLC	13.28 Billion USD	98.264%
Bristol-Myers Squibb Company PFD CONV 2	19.41 Billion USD	98.812%
CSPC Pharmaceutical Group Limited	1.14 Billion USD	79.909%
Clarus Therapeutics Holdings, Inc.	-39.7 Million USD	680.917%
Novartis AG	19.51 Billion USD	98.818%
PT Kalbe Farma Tbk.	288.13 Million USD	19.949%

Global Stocks Search

Virbac SA (VRBCF)

EBITDA Summary of Virbac SA

Annual EBITDA Chart of Virbac SA (2023 - 2002)

Historical Annual EBITDA of Virbac SA (2023 - 2002)

Peer EBITDA Comparison of Virbac SA